Elan Corp, plc (ADR) (NYSE:ELN)
The Company's Biopharmaceuticals unit is engaged in research, development and commercial activities and its EDT unit focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
AnsgarJohn
(47.22)
Submitted: 5/15/2013 5:32:47 AM :
Start Price:
$11.48
ELN Score:
+0.45
Seth Klarman pick: Moving into profit? http://www.gurufocus.com/stock/ELN
Recs
RandomStockPicks
(25.73)
Submitted: 4/17/2013 3:30:57 AM :
Start Price:
$11.75
ELN Score:
-7.50
Can a random number generator (www.random.org) produce the best 100 stock picks that will beat the market over the years? Let’s find out. :)
My process, for those interested:
I use www.random.org number generator to produce a number between 1 and 7,801. There are 7,801 stocks available to choose on the Motley Fool CAPS Game. Once I get a number, I go to the list, find that stock, and select that stock to outperform for the next five years.
Recs
dpid
(85.90)
Submitted: 2/6/2013 1:21:02 PM :
Start Price:
$9.44
ELN Score:
+12.80
gambling that this drug maker can become a investment fund vehicle after cash from sale of drug to Biogen
Recs
TMFCandyMountain
(99.79)
Submitted: 1/29/2013 3:22:34 PM :
Start Price:
$10.29
ELN Score:
+2.66
will show better profitability post spinoff
Recs
kprogers
(< 20)
Submitted: 9/8/2012 12:12:10 PM :
Start Price:
$11.31
ELN Score:
-12.64
Elan's development of ACC-001 has proven successful in Phase II trials. The company has an excellent ROE and strong ratings from analysts.
Recs
phatchips767
(< 20)
Submitted: 8/28/2012 2:11:08 PM :
Start Price:
$11.61
ELN Score:
-17.44
Irish biopharmacuetical company.
Recs
TMFDeej
(99.47)
Submitted: 8/13/2012 4:28:27 PM :
Start Price:
$11.75
ELN Score:
-18.84
As I have said many times in the past, I am certainly no fan ofthe pharma sector. Having said that, I do play special situations there from time to time. That's what I am doing here with Elan. I believe that the company's core business will benefit through lower expenses and in turn increased profitability from the spin-off of its discovery science and neotope biosciences operations.
Deej
Recs
Fool4Life30
(68.49)
Submitted: 3/22/2012 12:58:10 PM :
Start Price:
$14.73
ELN Score:
-40.56
Strong call volume recently suggests institutional traders are bullish on this company's Alzheimer's drug, this stock is a buy right here.
Recs
tommyboy1969
(< 20)
Submitted: 12/28/2010 6:49:04 PM :
Start Price:
$5.82
ELN Score:
+68.00
GUT PLAY
Recs
buckoblue31
(< 20)
Submitted: 10/30/2010 12:15:41 AM :
Start Price:
$5.44
ELN Score:
+74.32
Company has excelled in the past with it's tenacious performance with most of its trials. This kind of tynasity canot go unrewarded for to long a period.
Recs
mewag50
(< 20)
Submitted: 8/6/2010 6:34:45 PM :
Start Price:
$5.36
ELN Score:
+69.88
If not for poor management and many blunders by them, ELN would easily be well over $10 based on its science and pipeline, as well as Tysabri, which is well over $1 bil. and still has great growth potential.
Recs
anne1730
(74.01)
Submitted: 7/1/2010 5:54:25 PM :
Start Price:
$4.72
ELN Score:
+85.34
good product;; good research
Recs
asphall
(< 20)
Submitted: 6/11/2010 6:25:51 PM :
Start Price:
$5.11
ELN Score:
+77.33
too much taxes
Recs
Recs
watchit2
(< 20)
Submitted: 2/17/2010 4:41:51 AM :
Start Price:
$7.12
ELN Score:
-12.51
Dr.Paolo Zamboni has made a huge breakthrough in Multiple Sclerosis research. Sales of Tysabri will go down slow at first, then gain speed.
http://www.ctv.ca/servlet/ArticleNews/story/CTVNews/20091120/W5_liberation_091121/20091121?s_name=W5
Patients with Multiple Sclerosis and banding together to get tested and treated for Chronic Cerebral Spinal Insufficiency (CCSVI). Clinical trials already show a strong correlation between MS and CCSVI. A surgery (angioplasty or stents) on jugular veins are dramatically reducing symptoms of MS.
http://ccsvivictory.club.officelive.com/ConflictsofInterest.aspx
The four new cases of PML only makes things worse.
Recs
Recs
Contralogic
(24.70)
Submitted: 1/23/2010 10:19:08 AM :
Start Price:
$8.05
ELN Score:
-6.51
Elan -- will be a player in the biotech across the next 5 years.
Recs
wanttobelieve
(< 20)
Submitted: 12/14/2009 11:58:41 PM :
Start Price:
$6.45
ELN Score:
-31.15
Elan as a supply company is terrible!!! They are unable to manufacture and supply their own products. Take Azactam (aztreonam) an injectable antibiotic used in hospitals for example. They have a patent protection on the drug and yet have been unable to manufacture and supply it FOR OVER A YEAR!! If this is how the handle their research function then I want no part of it!
Recs
rainmaker59
(54.09)
Submitted: 11/11/2009 9:29:44 PM :
Start Price:
$6.32
ELN Score:
+32.89
Rulebreaker pick of Jan. 2009. All debt is related to massive R&D expenses. Leading edge of RX for Crohn's, MS and Alzheimer's.
Recs
macginty
(< 20)
Submitted: 10/29/2009 1:43:34 PM :
Start Price:
$5.19
ELN Score:
+68.00
The reason I feel that Eln will outperform is due to the underlying strength of a number of product lines in it's poertfolio e.g. the negative publicity regarding PML and Tysabri is exagerated and ignores the positive impact of the treatment on many lives.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 194 : 1 2 3 4 5 6 7 8 9 10 Next »